Navigate the OncoGenex OGXI research pages
Introduction (Financials, pipeline, milestones, catalysts, general info and links)
Custirsen aka OGX-011 (phase 3 asset for prostate and lung cancer partnered with TEVA, antisense targeting clusterin)
OGX-427 (phase 2 prostate and bladder cancer asset, unpartnered, antisense targeting HSP27)
Early pipeline products (all preclinical and focused on addressing mechanisms of cancer treatment resistance)
Custirsen aka OGX-011 (phase 3 asset for prostate and lung cancer partnered with TEVA, antisense targeting clusterin)
OGX-427 (phase 2 prostate and bladder cancer asset, unpartnered, antisense targeting HSP27)
Early pipeline products (all preclinical and focused on addressing mechanisms of cancer treatment resistance)
OGX-225
- Licensed from Isis Pharma 8/2003 for $0.75m upfront (in stock) and up to $3.5m milestones plus royalties
- Preclinical, 2nd generation antisense "designed to inhibit production of both Insulin Growth Factor Binding Protein 2, or IGFBP-2, and Insulin Growth Factor Binding Protein-5, or IGFBP-5. Increased IGFBP-2 or IGFBP-5 production is observed in many human cancers, including prostate, non-small cell lung, breast, ovarian, bladder, pancreatic and colon, as well as acute myeloid leukemia, acute lymphoblastic leukemia, neuroblastoma, glioma and melanoma. Increased IGFBP-2 or IGFBP-5 production is linked to faster rates of cancer progression, treatment resistance and shorter survival duration in humans." (2010 10k)
- Plan to use as monotherapy to attempt to delay disease progression in tumors that relay on IGF1 for proliferation
- 2010 10k: have not yet initiated pre-IND studies. No milestones yet achieved and did not appear in ISIS pipeline as of 12/31/10.
CSP-9222
- Preclinical, patents expire starting 2023 (licensed by predecessor Sonus in 4/2008 for $0.45m upfront, $0.1m+ annual maintenance fee, up to $14m milestones)
- This is "the lead compound from a family of caspase activators. These novel, small molecules have been identified as activators of programmed cell death in pre-clinical models." (2010 10k)
SN2310
- A novel camptothecin (potent anticancer agents that belong to the family of drugs called topoisomerase I inhibitors)
- Completed p1 trial in 2008 in 26 advanced cancer patients- DLT was neutropenia
- Outside of focus on treatment resistance, 1q2011 decided to stop trying to outlicense and ceased development
- IP owned by OGXI. Patents expire starting 2023